For the Quarter Ending December 2024
North America
During Q4 2024, the Etoricoxib (USP) market in North America demonstrated relative stability before experiencing a slight softening in December. The quarter began with balanced conditions as pharmaceutical manufacturers maintained routine procurement patterns amid adequate supply availability. US buyers operated with comfortable inventory positions while closely monitoring global supply dynamics.
The steady market conditions continued through November as supply chains operated efficiently and material remained readily available from both domestic and international sources. Major market participants maintained stable price positions, supported by consistent demand from pharmaceutical manufacturers and balanced inventory management strategies.
December brought modest downward pressure as year-end activities coincided with some destocking initiatives. Domestic suppliers adjusted offers slightly downward amid competitive market conditions and typical year-end inventory management. While the pharmaceutical sector's consumption patterns remained steady, the combination of adequate availability and strategic positioning by market participants led to some price erosion as the quarter concluded.
APAC
In Q4 2024, Etoricoxib (USP) prices in China maintained remarkable stability throughout the quarter. The market demonstrated steady fundamentals as producers effectively balanced production rates with demand requirements. Operations continued with stable market sentiment, supported by consistent domestic consumption and regular export inquiries.
Chinese manufacturers maintained steady price positions across the quarter, effectively managing production costs while meeting regular order flows. The market witnessed routine trading activity as both domestic and international buyers engaged in regular procurement. Regional trading patterns remained predictable as suppliers maintained disciplined pricing strategies aligned with stable demand fundamentals.
December saw continued price stability as manufacturers focused on maintaining balanced inventory positions. Production facilities reported steady capacity utilization rates amid regular order flows. The combination of well-managed supply conditions, consistent demand patterns, and strategic inventory control by producers helped maintain stable price levels. Export markets remained active with routine inquiries from international buyers supporting the market's stability.
Europe
In Q4 2024, Etoricoxib (USP) prices in Germany showed overall stability before encountering some weakness in December. The quarter began with balanced market fundamentals as buyers operated with adequate availability and steady offers from Asian suppliers. European importers maintained stable price positions through most of the quarter, supported by regular order flows and controlled procurement rates.
The steady market conditions continued through November as pharmaceutical sector demand remained consistent. Buyers engaged in routine procurement activities amid comfortable supply conditions and stable production costs. The market witnessed regular trading patterns as distributors maintained typical inventory levels.
December's market dynamics shifted slightly with modest price pressure as European distributors adjusted year-end positions. The combination of adequate supply availability and typical seasonal patterns led to some downward adjustment in prices. While consumption patterns remained steady across pharmaceutical applications, the market experienced slight softening through quarter-end, though the decline remained moderate and controlled.
